Multimodal treatment for t1-2 supraglottic cancer: the impact of tumor location
To examine the outcome and prognostic factors after multimodal treatment of T1-2 supraglottic cancer. We analyzed 49 patients with T1-2 supraglottic cancer who received multimodal treatment between 1990 and 2011. Their age range was 43-86 years (median=66 years). Fifteen patients had a T1 tumor and...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2014-01, Vol.34 (1), p.203-207 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 207 |
|---|---|
| container_issue | 1 |
| container_start_page | 203 |
| container_title | Anticancer research |
| container_volume | 34 |
| creator | Suzuki, Gen Yamazaki, Hideya Ogo, Etsuyo Abe, Toshi Hayabuchi, Naofumi Umeno, Hirohito Nakashima, Tadashi Nakamura, Satoaki Yoshida, Ken |
| description | To examine the outcome and prognostic factors after multimodal treatment of T1-2 supraglottic cancer.
We analyzed 49 patients with T1-2 supraglottic cancer who received multimodal treatment between 1990 and 2011. Their age range was 43-86 years (median=66 years). Fifteen patients had a T1 tumor and 34 had a T2 tumor (40 N0, 3 N1, 4 N2, and 2 N3). Debulking using transoral laser excision was employed in 25 patients. Neck dissection was performed in four patients. Chemotherapy was administered to 29 patients: intra-arterial infusion in four and systemic infusion in 25. Radiotherapy was administered at a median dose of 64.8 Gy (range=30-70 Gy) with once- or twice-daily fractionation. Median follow-up time was 60 months (range=12-153 months).
Two patients interrupted radiotherapy because of a poor response at 30 Gy (T2N2) and 49.9 Gy (T2N0). They underwent total laryngectomy and were still alive without any evidence of cancer 48 and 28 months after treatment, respectively. The other 47 patients (96%) had a complete local response to treatment. Locoregional failure was observed in six tumor sites, and one patient had simultaneous locoregional recurrence. The 5-year local control, disease-free, overall survival, and laryngeal preservation rates were 82%, 74%, 82%, and 90%, respectively. The location of a primary tumor within the supraglottis (epilarynx or elsewhere) was identified as the only factor predictive of progression-free survival by univariate and multivariate analyses (p=0.04). Acute adverse reactions of grade 3 or more were: one grade 3 laryngeal edema, one grade 3 dyspnea, and one grade 5 hematological toxicity (disseminated intravascular coagulation). Among late adverse events, one grade 1, one grade 2 hoarseness, and grade 3 laryngeal necrosis were observed.
Multimodal radiotherapy produced a good outcome. Localization of the tumor in the epilarynx was associated with a better progression-free survival rate than that in the other parts of the supraglottis. |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1490748123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1490748123</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-1a4f8c8370718c3228f121dec8770b4e7398dc92ccaa9f3387d024a036f8d4933</originalsourceid><addsrcrecordid>eNo10DtLBDEYheEgiLuu_gVJaTOQm5PEThZvsLKN1sO3uehIMhmTbwr_vYpanebhFO8RWXNteaevJFuR09beGet7a-QJWQmlmFS9XJP905JwzMVDolgDYA4T0lgqRd4J2pa5wmsqiKOjDiYX6jXFt0DHPINDWiLFJX_rVBzgWKYzchwhtXD-txvycnf7vH3odvv7x-3NrpsF59hxUNE4IzXT3DgphIlccB-c0ZodVNDSGu-scA7ARimN9kwoYLKPxisr5YZc_v7OtXwsoeGQx-ZCSjCFsrSBK8u0Mlz80Is_uhxy8MNcxwz1c_iPIL8AtWhWxQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1490748123</pqid></control><display><type>article</type><title>Multimodal treatment for t1-2 supraglottic cancer: the impact of tumor location</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Suzuki, Gen ; Yamazaki, Hideya ; Ogo, Etsuyo ; Abe, Toshi ; Hayabuchi, Naofumi ; Umeno, Hirohito ; Nakashima, Tadashi ; Nakamura, Satoaki ; Yoshida, Ken</creator><creatorcontrib>Suzuki, Gen ; Yamazaki, Hideya ; Ogo, Etsuyo ; Abe, Toshi ; Hayabuchi, Naofumi ; Umeno, Hirohito ; Nakashima, Tadashi ; Nakamura, Satoaki ; Yoshida, Ken</creatorcontrib><description>To examine the outcome and prognostic factors after multimodal treatment of T1-2 supraglottic cancer.
We analyzed 49 patients with T1-2 supraglottic cancer who received multimodal treatment between 1990 and 2011. Their age range was 43-86 years (median=66 years). Fifteen patients had a T1 tumor and 34 had a T2 tumor (40 N0, 3 N1, 4 N2, and 2 N3). Debulking using transoral laser excision was employed in 25 patients. Neck dissection was performed in four patients. Chemotherapy was administered to 29 patients: intra-arterial infusion in four and systemic infusion in 25. Radiotherapy was administered at a median dose of 64.8 Gy (range=30-70 Gy) with once- or twice-daily fractionation. Median follow-up time was 60 months (range=12-153 months).
Two patients interrupted radiotherapy because of a poor response at 30 Gy (T2N2) and 49.9 Gy (T2N0). They underwent total laryngectomy and were still alive without any evidence of cancer 48 and 28 months after treatment, respectively. The other 47 patients (96%) had a complete local response to treatment. Locoregional failure was observed in six tumor sites, and one patient had simultaneous locoregional recurrence. The 5-year local control, disease-free, overall survival, and laryngeal preservation rates were 82%, 74%, 82%, and 90%, respectively. The location of a primary tumor within the supraglottis (epilarynx or elsewhere) was identified as the only factor predictive of progression-free survival by univariate and multivariate analyses (p=0.04). Acute adverse reactions of grade 3 or more were: one grade 3 laryngeal edema, one grade 3 dyspnea, and one grade 5 hematological toxicity (disseminated intravascular coagulation). Among late adverse events, one grade 1, one grade 2 hoarseness, and grade 3 laryngeal necrosis were observed.
Multimodal radiotherapy produced a good outcome. Localization of the tumor in the epilarynx was associated with a better progression-free survival rate than that in the other parts of the supraglottis.</description><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 24403463</identifier><language>eng</language><publisher>Greece</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Carcinoma, Squamous Cell - mortality ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - therapy ; Cisplatin - administration & dosage ; Combined Modality Therapy ; Dose Fractionation ; Female ; Fluorouracil - administration & dosage ; Follow-Up Studies ; Glottis - pathology ; Humans ; Laryngeal Neoplasms - mortality ; Laryngeal Neoplasms - pathology ; Laryngeal Neoplasms - therapy ; Laryngectomy ; Male ; Middle Aged ; Neoplasm Recurrence, Local - mortality ; Neoplasm Recurrence, Local - pathology ; Neoplasm Recurrence, Local - therapy ; Neoplasm Staging ; Prognosis ; Radiotherapy Dosage ; Survival Rate</subject><ispartof>Anticancer research, 2014-01, Vol.34 (1), p.203-207</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24403463$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Suzuki, Gen</creatorcontrib><creatorcontrib>Yamazaki, Hideya</creatorcontrib><creatorcontrib>Ogo, Etsuyo</creatorcontrib><creatorcontrib>Abe, Toshi</creatorcontrib><creatorcontrib>Hayabuchi, Naofumi</creatorcontrib><creatorcontrib>Umeno, Hirohito</creatorcontrib><creatorcontrib>Nakashima, Tadashi</creatorcontrib><creatorcontrib>Nakamura, Satoaki</creatorcontrib><creatorcontrib>Yoshida, Ken</creatorcontrib><title>Multimodal treatment for t1-2 supraglottic cancer: the impact of tumor location</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>To examine the outcome and prognostic factors after multimodal treatment of T1-2 supraglottic cancer.
We analyzed 49 patients with T1-2 supraglottic cancer who received multimodal treatment between 1990 and 2011. Their age range was 43-86 years (median=66 years). Fifteen patients had a T1 tumor and 34 had a T2 tumor (40 N0, 3 N1, 4 N2, and 2 N3). Debulking using transoral laser excision was employed in 25 patients. Neck dissection was performed in four patients. Chemotherapy was administered to 29 patients: intra-arterial infusion in four and systemic infusion in 25. Radiotherapy was administered at a median dose of 64.8 Gy (range=30-70 Gy) with once- or twice-daily fractionation. Median follow-up time was 60 months (range=12-153 months).
Two patients interrupted radiotherapy because of a poor response at 30 Gy (T2N2) and 49.9 Gy (T2N0). They underwent total laryngectomy and were still alive without any evidence of cancer 48 and 28 months after treatment, respectively. The other 47 patients (96%) had a complete local response to treatment. Locoregional failure was observed in six tumor sites, and one patient had simultaneous locoregional recurrence. The 5-year local control, disease-free, overall survival, and laryngeal preservation rates were 82%, 74%, 82%, and 90%, respectively. The location of a primary tumor within the supraglottis (epilarynx or elsewhere) was identified as the only factor predictive of progression-free survival by univariate and multivariate analyses (p=0.04). Acute adverse reactions of grade 3 or more were: one grade 3 laryngeal edema, one grade 3 dyspnea, and one grade 5 hematological toxicity (disseminated intravascular coagulation). Among late adverse events, one grade 1, one grade 2 hoarseness, and grade 3 laryngeal necrosis were observed.
Multimodal radiotherapy produced a good outcome. Localization of the tumor in the epilarynx was associated with a better progression-free survival rate than that in the other parts of the supraglottis.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Carcinoma, Squamous Cell - mortality</subject><subject>Carcinoma, Squamous Cell - pathology</subject><subject>Carcinoma, Squamous Cell - therapy</subject><subject>Cisplatin - administration & dosage</subject><subject>Combined Modality Therapy</subject><subject>Dose Fractionation</subject><subject>Female</subject><subject>Fluorouracil - administration & dosage</subject><subject>Follow-Up Studies</subject><subject>Glottis - pathology</subject><subject>Humans</subject><subject>Laryngeal Neoplasms - mortality</subject><subject>Laryngeal Neoplasms - pathology</subject><subject>Laryngeal Neoplasms - therapy</subject><subject>Laryngectomy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Recurrence, Local - mortality</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Recurrence, Local - therapy</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Radiotherapy Dosage</subject><subject>Survival Rate</subject><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo10DtLBDEYheEgiLuu_gVJaTOQm5PEThZvsLKN1sO3uehIMhmTbwr_vYpanebhFO8RWXNteaevJFuR09beGet7a-QJWQmlmFS9XJP905JwzMVDolgDYA4T0lgqRd4J2pa5wmsqiKOjDiYX6jXFt0DHPINDWiLFJX_rVBzgWKYzchwhtXD-txvycnf7vH3odvv7x-3NrpsF59hxUNE4IzXT3DgphIlccB-c0ZodVNDSGu-scA7ARimN9kwoYLKPxisr5YZc_v7OtXwsoeGQx-ZCSjCFsrSBK8u0Mlz80Is_uhxy8MNcxwz1c_iPIL8AtWhWxQ</recordid><startdate>201401</startdate><enddate>201401</enddate><creator>Suzuki, Gen</creator><creator>Yamazaki, Hideya</creator><creator>Ogo, Etsuyo</creator><creator>Abe, Toshi</creator><creator>Hayabuchi, Naofumi</creator><creator>Umeno, Hirohito</creator><creator>Nakashima, Tadashi</creator><creator>Nakamura, Satoaki</creator><creator>Yoshida, Ken</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201401</creationdate><title>Multimodal treatment for t1-2 supraglottic cancer: the impact of tumor location</title><author>Suzuki, Gen ; Yamazaki, Hideya ; Ogo, Etsuyo ; Abe, Toshi ; Hayabuchi, Naofumi ; Umeno, Hirohito ; Nakashima, Tadashi ; Nakamura, Satoaki ; Yoshida, Ken</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-1a4f8c8370718c3228f121dec8770b4e7398dc92ccaa9f3387d024a036f8d4933</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Carcinoma, Squamous Cell - mortality</topic><topic>Carcinoma, Squamous Cell - pathology</topic><topic>Carcinoma, Squamous Cell - therapy</topic><topic>Cisplatin - administration & dosage</topic><topic>Combined Modality Therapy</topic><topic>Dose Fractionation</topic><topic>Female</topic><topic>Fluorouracil - administration & dosage</topic><topic>Follow-Up Studies</topic><topic>Glottis - pathology</topic><topic>Humans</topic><topic>Laryngeal Neoplasms - mortality</topic><topic>Laryngeal Neoplasms - pathology</topic><topic>Laryngeal Neoplasms - therapy</topic><topic>Laryngectomy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Recurrence, Local - mortality</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Recurrence, Local - therapy</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Radiotherapy Dosage</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Suzuki, Gen</creatorcontrib><creatorcontrib>Yamazaki, Hideya</creatorcontrib><creatorcontrib>Ogo, Etsuyo</creatorcontrib><creatorcontrib>Abe, Toshi</creatorcontrib><creatorcontrib>Hayabuchi, Naofumi</creatorcontrib><creatorcontrib>Umeno, Hirohito</creatorcontrib><creatorcontrib>Nakashima, Tadashi</creatorcontrib><creatorcontrib>Nakamura, Satoaki</creatorcontrib><creatorcontrib>Yoshida, Ken</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Suzuki, Gen</au><au>Yamazaki, Hideya</au><au>Ogo, Etsuyo</au><au>Abe, Toshi</au><au>Hayabuchi, Naofumi</au><au>Umeno, Hirohito</au><au>Nakashima, Tadashi</au><au>Nakamura, Satoaki</au><au>Yoshida, Ken</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Multimodal treatment for t1-2 supraglottic cancer: the impact of tumor location</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2014-01</date><risdate>2014</risdate><volume>34</volume><issue>1</issue><spage>203</spage><epage>207</epage><pages>203-207</pages><eissn>1791-7530</eissn><abstract>To examine the outcome and prognostic factors after multimodal treatment of T1-2 supraglottic cancer.
We analyzed 49 patients with T1-2 supraglottic cancer who received multimodal treatment between 1990 and 2011. Their age range was 43-86 years (median=66 years). Fifteen patients had a T1 tumor and 34 had a T2 tumor (40 N0, 3 N1, 4 N2, and 2 N3). Debulking using transoral laser excision was employed in 25 patients. Neck dissection was performed in four patients. Chemotherapy was administered to 29 patients: intra-arterial infusion in four and systemic infusion in 25. Radiotherapy was administered at a median dose of 64.8 Gy (range=30-70 Gy) with once- or twice-daily fractionation. Median follow-up time was 60 months (range=12-153 months).
Two patients interrupted radiotherapy because of a poor response at 30 Gy (T2N2) and 49.9 Gy (T2N0). They underwent total laryngectomy and were still alive without any evidence of cancer 48 and 28 months after treatment, respectively. The other 47 patients (96%) had a complete local response to treatment. Locoregional failure was observed in six tumor sites, and one patient had simultaneous locoregional recurrence. The 5-year local control, disease-free, overall survival, and laryngeal preservation rates were 82%, 74%, 82%, and 90%, respectively. The location of a primary tumor within the supraglottis (epilarynx or elsewhere) was identified as the only factor predictive of progression-free survival by univariate and multivariate analyses (p=0.04). Acute adverse reactions of grade 3 or more were: one grade 3 laryngeal edema, one grade 3 dyspnea, and one grade 5 hematological toxicity (disseminated intravascular coagulation). Among late adverse events, one grade 1, one grade 2 hoarseness, and grade 3 laryngeal necrosis were observed.
Multimodal radiotherapy produced a good outcome. Localization of the tumor in the epilarynx was associated with a better progression-free survival rate than that in the other parts of the supraglottis.</abstract><cop>Greece</cop><pmid>24403463</pmid><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1791-7530 |
| ispartof | Anticancer research, 2014-01, Vol.34 (1), p.203-207 |
| issn | 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1490748123 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Carcinoma, Squamous Cell - mortality Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - therapy Cisplatin - administration & dosage Combined Modality Therapy Dose Fractionation Female Fluorouracil - administration & dosage Follow-Up Studies Glottis - pathology Humans Laryngeal Neoplasms - mortality Laryngeal Neoplasms - pathology Laryngeal Neoplasms - therapy Laryngectomy Male Middle Aged Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - pathology Neoplasm Recurrence, Local - therapy Neoplasm Staging Prognosis Radiotherapy Dosage Survival Rate |
| title | Multimodal treatment for t1-2 supraglottic cancer: the impact of tumor location |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T16%3A53%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Multimodal%20treatment%20for%20t1-2%20supraglottic%20cancer:%20the%20impact%20of%20tumor%20location&rft.jtitle=Anticancer%20research&rft.au=Suzuki,%20Gen&rft.date=2014-01&rft.volume=34&rft.issue=1&rft.spage=203&rft.epage=207&rft.pages=203-207&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1490748123%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1490748123&rft_id=info:pmid/24403463&rfr_iscdi=true |